During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, US, about the CARTITUDE-1 study. We asked, Are responses with ciltacabtagene autoleucel (cilta-cel) deep and durable?